{"product_id":"iqvia-five-forces-analysis","title":"IQVIA Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eIQVIA faces intense competitive rivalry, high buyer power from large pharma clients, moderate supplier influence tied to data sources, limited threat from new entrants due to scale and regulatory barriers, and evolving substitute threats from tech-enabled analytics; this snapshot highlights strategic pressures shaping its performance.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore IQVIA’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to Specialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary supplier input for IQVIA is a specialized workforce—data scientists, clinical research associates, and medical experts—whose scarcity drives supplier power.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, estimates show a global shortfall of ~40,000 bioinformatics and clinical trial specialists, increasing salary premiums; IQVIA must match median industry pay rises of 8–12% seen in 2024–25 to stay competitive.\u003c\/p\u003e\n\u003cp\u003eIQVIA invests in continuous professional development and retention bonuses because losing staff would forfeit proprietary data models and trial know-how, costing millions in delayed studies and lost contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Cloud and AI Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIQVIA depends on AWS, Microsoft Azure and Google Cloud to process \u0026gt;250 petabytes of health data and run AI models; deep integration into its Orchestrated Analytics platforms raises switching costs and integration risk.\u003c\/p\u003e\n\u003cp\u003eThat creates moderate supplier power: cloud providers can influence pricing and SLAs—AWS average enterprise price increases ~6–8% in 2024—yet competition and multi-cloud strategies limit full supplier leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Acquisition and Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA sources anonymized patient data from pharmacies, hospitals, and insurers globally, feeding its CORE dataset which generated about $10.2B revenue in 2024; long-term contracts lower supplier churn. \u003c\/p\u003e\n\u003cp\u003eRising privacy rules—updated GDPR guidance in 2023 and US state laws like California CPA expansions—give data originators leverage to demand higher compliance, audits, and fees, raising sourcing costs by an estimated 3–6% annually. \u003c\/p\u003e\n\u003cp\u003eIQVIA must renegotiate terms continuously to preserve data integrity and volume, invest in tech and legal compliance (millions annually), and accept some price sensitivity from suppliers. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Site Availability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical trial sites—academic medical centers and private clinics—are scarce: top sites run ~30–50 active studies annually and enroll 40–60% of phase II\/III patients, giving them leverage over CROs like IQVIA.\u003c\/p\u003e\n\u003cp\u003eSites can favor sponsors or charge higher per-patient site fees and overheads; in 2024 median site startup payments rose ~12% to $25k–$40k, increasing supplier bargaining power.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh demand: major CROs compete for same sites\u003c\/li\u003e\n\u003cli\u003eConcentration: top 10% sites deliver ~50% enrollments\u003c\/li\u003e\n\u003cli\u003ePricing power: site fees +12% in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Laboratory and Equipment Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIQVIA depends on niche medical-tech suppliers for specialized diagnostics and reagents; in 2024 about 60–75% of certified clinical lab components came from fewer than 10 manufacturers, concentrating supplier power.\u003c\/p\u003e\n\u003cp\u003eThese components face tight regulation (FDA\/EMA), long lead times, and single-source certifications, so supply disruption can delay trials and revenue recognition by months, giving vendors tactical leverage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60–75% of key lab components from \u0026lt;10 firms (2024)\u003c\/li\u003e\n\u003cli\u003eFDA\/EMA certification increases switching time to 6–12 months\u003c\/li\u003e\n\u003cli\u003eSingle-source parts can delay trials by 1–6 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers Hold Sway: Workforce Shortages, Cloud Hikes, Data Costs \u0026amp; Component Delays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers exert moderate-to-high power: scarce skilled staff (≈40,000 shortfall by end-2025; 8–12% pay inflation 2024–25), three major cloud providers (AWS price rises ~6–8% in 2024), CORE data driving $10.2B revenue (2024) with 3–6% compliance cost rise, site fees +12% (2024), and 60–75% of lab components from \u0026lt;10 firms causing 1–6 month trial delays.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003e~40,000 shortfall (2025); 8–12% pay rise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud\u003c\/td\u003e\n\u003ctd\u003eAWS +6–8% price rise (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData\u003c\/td\u003e\n\u003ctd\u003eCORE $10.2B (2024); +3–6% compliance cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003eSite fees +12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab components\u003c\/td\u003e\n\u003ctd\u003e60–75% from \u0026lt;10 firms; 1–6m delays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for IQVIA, this Porter's Five Forces analysis uncovers key competitive drivers, buyer and supplier power, entry barriers, substitutes, and disruptive threats shaping IQVIA’s pricing, profitability, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIQVIA Porter's Five Forces distilled into one concise sheet—fast, board-ready insights to pinpoint competitive pressures and inform strategic moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Big Pharma Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of iqvia revenue in from a handful global pharma giants giving those clients outsized bargaining power. these customers leverage large r budgets totaled roughly to demand volume discounts and bespoke slas. ongoing consolidation style=\"\" deals\u003e10 major M\u0026amp;A moves in 2021–24—further concentrates purchasing power, raising margin pressure on IQVIA.\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Integrated Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClients using IQVIA OCE and integrated analytics face high switching costs: migrating data, retraining staff, and reconfiguring workflows can take 6–12+ months and cost tens of millions for large pharma accounts, per industry surveys in 2024; that deep tech and data integration embeds IQVIA into daily commercial ops and raises exit barriers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of Small and Mid-Sized Biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe rise of small and mid-sized biotech firms has fragmented IQVIA’s customer base, reducing individual bargaining power compared with Big Pharma; by 2024 there were ~12,000 global biotech firms vs ~750 pharma majors, shifting spend toward vendors. \u003c\/p\u003e\n\u003cp\u003eMany smaller biotechs lack trial and analytics infrastructure, so they outsource end-to-end services to IQVIA—outsourcing rates for SMEs rose ~18% from 2019–2023—boosting IQVIA’s negotiating leverage. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Demonstrated ROI and Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy end-2025, roughly 28% of large pharma contracts shift to outcome-based pricing where payments tie to clinical milestones, pushing customers to demand demonstrated ROI and raising their bargaining power; IQVIA must absorb greater performance risk and accept stricter financial terms.\u003c\/p\u003e\n\u003cp\u003eIQVIA counters by using predictive analytics—real-world evidence and AI-driven trial simulation—which it claims cut trial failure risk by ~18% and shortens timelines by 12%, strengthening its negotiating stance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~28% large-pharma contracts outcome-based (2025)\u003c\/li\u003e\n\u003cli\u003eIQVIA analytics cut failure risk ~18%\u003c\/li\u003e\n\u003cli\u003eTimeline reduction ~12%\u003c\/li\u003e\n\u003cli\u003eCustomers gain pricing leverage; IQVIA assumes more risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity in Standardized Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn commoditized areas like basic Phase III monitoring and standard data reporting, buyers are highly price sensitive as many rivals offer similar services; industry sourcing surveys in 2024 showed 62% of sponsors prioritize cost for these tasks.\u003c\/p\u003e\n\u003cp\u003eIQVIA reduces this pressure by bundling standardized services with proprietary real-world data and analytics—clients report average cost-per-study savings of 8–12% and faster site selection by 18% versus pure-play CROs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of sponsors prioritize cost (2024 survey)\u003c\/li\u003e\n\u003cli\u003eMany competitors offer near-identical functional services\u003c\/li\u003e\n\u003cli\u003eIQVIA bundles services with proprietary data\u003c\/li\u003e\n\u003cli\u003eReported 8–12% cost savings and 18% faster site selection\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIQVIA: Top‑client concentration fuels buyer power; high switching costs meet rising outcome demands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpcustomers concentrated: of iqvia revenue came from top pharma giving outsized buyer power consolidation\u003e10 major M\u0026amp;A deals 2021–24) raised pressure. Switching costs are high—6–12+ months, tens of millions—locking clients in, while SME outsourcing (+18% 2019–23) and ~12,000 biotechs dilute single-buyer leverage. Outcome-based contracts (~28% by end‑2025) raise customer demands; IQVIA claims analytics cut trial failure ~18% and timelines ~12%.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-client revenue share (2024)\u003c\/td\u003e\n\u003ctd\u003e~40% of $13.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig Pharma R\u0026amp;D (2023)\u003c\/td\u003e\n\u003ctd\u003e~$200B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech count (2024)\u003c\/td\u003e\n\u003ctd\u003e~12,000 firms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSME outsourcing growth\u003c\/td\u003e\n\u003ctd\u003e+18% (2019–23)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutcome-based contracts (2025)\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIQVIA claimed effects\u003c\/td\u003e\n\u003ctd\u003eFailure risk −18%, timelines −12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pcustomers\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eIQVIA Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact IQVIA Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders or samples.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the full, professionally formatted file—ready to download and use the moment you buy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746679599481,"sku":"iqvia-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/iqvia-five-forces-analysis.png?v=1772190860","url":"https:\/\/growthsharematrix.com\/products\/iqvia-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}